Fresenius Kabi has announced the availability of Fulvestrant Injection 250mg/5mL prefilled syringe that is stable at room temperature. The product is bioequivalent to Faslodex (AstraZeneca).

(Logo: http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO) "This approval is an important advancement for women with metastatic breast cancer, where the ...

The FDA has approved label changes for AstraZeneca‘s Faslodex (fulvestrant) injection. Labeling updates include results and a Kaplan-Meier plot of the final overall survival (OS) analysis from CONFIRM ...

LAKE ZURICH, Ill.--(BUSINESS WIRE)--Fresenius Kabi announced today the immediate availability in the United States of Fulvestrant Injection 250mg per 5mL prefilled syringe, an expansion of the company ...

HYDERABAD, India & PRINCETON, N.J.--(BUSINESS WIRE)--Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today ...

(RTTNews) - Dr. Reddy's Laboratories Ltd. (RDY), an integrated pharmaceutical company, announced the launch of Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per single-dose syringe, a therapeutic ...

Fresenius Kabi is offering fulvestrant injection in a 250mg per 5mL prefilled syringe. Fresenius Kabi developed its fulvestrant injection prefilled syringe to be stable at room temperature, making it ...

(NYSE:AZN) today announced the start of a Phase III study (FALCON), a global clinical trial which will involve 450 postmenopausal patients with hormone receptor-positive locally advanced or metastatic ...

First-Line Chemotherapy With Cisplatin Plus Fractionated Temozolomide in Recurrent Glioblastoma Multiforme: A Phase II Study of the Gruppo Italiano Cooperativo di Neuro-Oncologia In this multicenter, ...

(RTTNews) - Dr. Reddy's Laboratories Ltd. (RDY), an integrated pharmaceutical company, announced the launch of Fulvestrant Injection, 250 mg/5 mL (50 mg/mL) per single-dose syringe, a therapeutic ...